LGALS1 and myeloid neoplasm: Targeting galectin-1 using small molecule glycan inhibitors, natural polysaccharides, peptides (OTX008) or anti-galectin-1 monoclonal antibodies may counteract fibrosis and also the immunomodulation that occurs in myeloid neoplasms (61, 63).